{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:00:48Z","timestamp":1778616048531,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Bone and joint infections (BJIs) caused by multidrug-resistant bacteria are becoming more frequent. However, data on the use of novel \u03b2-lactam\/\u03b2-lactamase inhibitors, such as imipenem\/cilastatin\/relebactam (I-R) and meropenem\/vaborbactam (MVB), to treat BJIs is lacking. Furthermore, prolonged infusions of these \u03b2-lactams should theoretically optimize pharmacokinetic\/pharmacodynamics target in these indications, but there are currently no reports on this type of infusions, especially in the setting of BJI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>We report a case of a vertebral osteomyelitis caused by carbapenem-resistant <jats:italic>Enterobacter cloacae<\/jats:italic> successfully treated with extended-infusion of I-R (1.25\u00a0g q6h over 2\u00a0h), then with continuous infusion of MVB (2\u00a0g q4h as over 4\u00a0h). Therapeutic drug monitoring confirmed that extended-infusion of I-R and continuous infusion of MVB achieved serum concentrations up to 12\u00a0mg\/L of imipenem and 19\u00a0mg\/L of meropenem, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The favourable outcome of this patient treated for a vertebral osteomyelitis caused by carbapenem-resistant <jats:italic>E. cloacae<\/jats:italic> suggest that extended- and continuous infusions of I-R and MVB, are promising regimens for treatment of BJIs caused by carbapenem-resistant Enterobacterales.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1347306","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T10:15:12Z","timestamp":1730283312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem\/cilastatin\/relebactam prolonged infusion then meropenem\/vaborbactam in continuous infusion"],"prefix":"10.3389","volume":"15","author":[{"given":"Paul","family":"Laffont-Lozes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayma","family":"Naciri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Pruvot-Occean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Haignere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romaric","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper<sub\/>","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.accpm.2019.02.015","article-title":"PHARMECMO: therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support","volume":"38","author":"Bougl\u00e9","year":"2019","journal-title":"Anaesth. Crit. Care and Pain Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"ofaa054","DOI":"10.1093\/ofid\/ofaa054","article-title":"Evaluation of renal safety between imipenem\/relebactam and colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections in the randomized, phase 3 RESTORE-IMI 1 study","volume":"7","author":"Brown","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"106702","DOI":"10.1016\/j.ijantimicag.2022.106702","article-title":"Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae","volume":"61","author":"Davido","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jiph.2024.03.010","article-title":"Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: a propensity score analysis","volume":"17","author":"Katip","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s15010-023-02055-2","article-title":"Continuous infusion of meropenem\u2013vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance","volume":"51","author":"Larcher","year":"2023","journal-title":"Infection"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1048633","DOI":"10.3389\/fcimb.2022.1048633","article-title":"Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: a real-life study","volume":"12","author":"Larcher","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/antibiotics11040486","article-title":"Antibiotic therapy for prosthetic joint infections: an overview","volume":"11","author":"Le Vavasseur","year":"2022","journal-title":"Antibiotics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijantimicag.2018.10.018","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: role of surgery and impact of colistin administration","volume":"53","author":"Papadopoulos","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B13","doi-asserted-by":"publisher","first-page":"ofab554","DOI":"10.1093\/ofid\/ofab554","article-title":"Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections","volume":"8","author":"Rebold","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B14","unstructured":"Summary of product characteristics: Recarbrio2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jgar.2021.04.003","article-title":"Treatment of bone and joint infections by ceftazidime\/avibactam and ceftolozane\/tazobactam: a cohort study","volume":"25","author":"Rempenault","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e01411","DOI":"10.1128\/aac.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel \u03b2-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B20","unstructured":"Summary of product characteristics: Vaborem2018"},{"key":"B21","doi-asserted-by":"publisher","first-page":"00775-17","DOI":"10.1128\/AAC.00775-17","article-title":"Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem\u2013vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1347306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T10:15:14Z","timestamp":1730283314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1347306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":22,"alternative-id":["10.3389\/fphar.2024.1347306"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1347306","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1347306"}}